<DOC>
	<DOCNO>NCT00002488</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist cyclophosphamide , etoposide , cisplatin treat patient intermediate high-grade non-Hodgkin 's lymphoma relapse follow resistant anthracycline-containing primary combination chemotherapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Intermediate-Grade High-Grade Non-Hodgkin 's Lymphoma Who Have Not Responded Anthracycline-Containing Combination Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy high-dose cyclophosphamide/etoposide/cisplatin patient intermediate- high-grade non-Hodgkin 's lymphoma fail primary combination chemotherapy still respond conventional-dose DHAP ( dexamethasone/cytarabine/cisplatin ) candidate bone marrow transplantation . II . Determine toxicity intensification chemotherapy regimen group patient . OUTLINE : Nonrandomized study . 3-Drug Combination Chemotherapy . CVP : Cyclophosphamide , CTX , NSC-26271 ; Etoposide , VP-16 , NSC-141540 ; Cisplatin , CDDP , NSC-119875 . PROJECTED ACCRUAL : If least 1 CR see first 6 patient , estimate maximum 20 patient enrol . If 3 first 10 patient ( 25 % study population thereafter ) die within first 35 day treatment cause unrelated tumor progression , study terminate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intermediate highgrade non Hodgkin 's lymphoma follow histology : Follicular , predominantly large cell Diffuse small cleave cell Diffuse mix , small large cell Diffuse large cell Large cell , immunoblastic Lymphoblastic Small noncleaved cell Disease relapse follow resistant primary anthracyclinecontaining combination chemotherapy Objective response salvage DHAP chemotherapy require Ineligible bone marrow transplantation PATIENT CHARACTERISTICS : Age : 18 64 Performance status : Zubrod 0 1 Hematopoietic : ANC least 1,500 Platelets least 140,000 Hb least 10 g/dl Hepatic : Bilirubin le 1.5 mg/dl ( 26 micromoles/liter ) SGOT le 4 x normal Renal : Creatinine le 1.5 mg/dl ( 133 micromoles/liter ) Cardiovascular : LVEF great 50 % No lifethreatening arrhythmia EKG No uncontrolled hypertension Pulmonary : FEV , FVC , DLCO great 50 % predict Other : No uncontrolled diabetes No uncontrolled medical condition No history second malignancy except : Nonmelanomatous skin cancer Carcinoma situ Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior anthracyclinecontaining combination chemotherapy require Prior salvage DHAP chemotherapy require Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
</DOC>